- Home
- KGS vs DYN Comparison
KGS vs DYN Comparison
Compare KGS & DYN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KGS
- DYN
- Stock Information
- Founded
- KGS 2011
- DYN 1984
- Country
- KGS United States
- DYN United States
- Employees
- KGS N/A
- DYN N/A
- Industry
- KGS
- DYN Medicinal Chemicals and Botanical Products
- Sector
- KGS
- DYN Health Care
- Exchange
- KGS Nasdaq
- DYN Nasdaq
- Market Cap
- KGS 2.6B
- DYN 2.6B
- IPO Year
- KGS 2023
- DYN 2020
- Fundamental
- Price
- KGS $41.12
- DYN $26.16
- Analyst Decision
- KGS Strong Buy
- DYN Strong Buy
- Analyst Count
- KGS 11
- DYN 11
- Target Price
- KGS $37.09
- DYN $51.18
- AVG Volume (30 Days)
- KGS 834.0K
- DYN 836.3K
- Earning Date
- KGS 11-06-2024
- DYN 11-12-2024
- Dividend Yield
- KGS 3.95%
- DYN N/A
- EPS Growth
- KGS N/A
- DYN N/A
- EPS
- KGS 0.26
- DYN N/A
- Revenue
- KGS $1,075,772,000.00
- DYN N/A
- Revenue This Year
- KGS $38.17
- DYN N/A
- Revenue Next Year
- KGS $15.83
- DYN N/A
- P/E Ratio
- KGS $158.31
- DYN N/A
- Revenue Growth
- KGS 33.77
- DYN N/A
- 52 Week Low
- KGS $19.17
- DYN $11.66
- 52 Week High
- KGS $44.20
- DYN $47.45
- Technical
- Relative Strength Index (RSI)
- KGS 60.09
- DYN 39.20
- Support Level
- KGS $40.27
- DYN $25.08
- Resistance Level
- KGS $41.90
- DYN $28.96
- Average True Range (ATR)
- KGS 1.18
- DYN 1.54
- MACD
- KGS -0.28
- DYN -0.26
- Stochastic Oscillator
- KGS 34.02
- DYN 17.31
About KGS Kodiak Gas Services Inc.
Kodiak Gas Services Inc is an operator of contract compression infrastructure in the United States. It manages business through two operating segments namely Compression Operations and Other Services. Compression Operations consist of operating company-owned and customer-owned compression infrastructure for customers, pursuant to fixed-revenue contracts to enable the production, gathering and transportation of natural gas and oil. Other Services consist of a full range of contract services to support the needs of customers, including station construction, maintenance and overhaul and other ancillary time and material-based offerings.
About DYN Dyne Therapeutics Inc.
Dyne Therapeutics Inc is a biotechnology company focused on providing therapeutics for patients with genetically driven diseases. The company overcomes the limitations of muscle tissue delivery and modern oligonucleotide therapeutics for muscle diseases. The company is developing therapies for muscle disorders like Myotonic dystrophy, Duchenne muscular dystrophy, and Facioscapulohumeral muscular dystrophy. The company's product candidates are DYNE-101 and DYNE-251, both are in the ongoing phase 1/2 clinical trial.